ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30

Alzamend Neuro, Inc.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026

$1.33+0.03 (+2.31%)

Close on Oct 19, 2026

Market cap: $5.96M
P/E (TTM): –
Dividend yield: –

Alzamend Neuro, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q1 2027 2026-07-31	Q4 2026 2026-04-30	Q3 2026 2026-01-31	Q2 2026 2025-10-31	Q1 2026 2025-07-31	Q4 2025 2025-04-30	Q1 2025 2024-07-31	Q4 2024 2024-04-30	Q3 2024 2024-01-31	Q2 2024 2023-10-31	Q1 2024 2023-07-31	Q4 2023 2023-04-30	Q3 2023 2023-01-31	Q2 2023 2022-10-31	Q1 2023 2022-07-31	Q4 2022 2022-04-30	Q3 2022 2022-01-31	Q2 2022 2021-10-31	Q1 2022 2021-07-31	Q4 2021 2021-04-30	Q3 2021 2021-01-31	Q2 2021 2020-10-31	Q1 2021 2020-07-31	Q4 2020 2020-04-30	Q4 2019 2019-04-30
Cash & Equivalents	7.59	0.71	2.71	4.45	5.62	3.95	1.19	0.38	0.28	0.20	1.70	5.14	7.38	9.18	12	14	12	14	16	1.93	0.04	0.01	0.06	0.09	0.04
Cash & Short-Term Investments	7.59	0.71	2.71	4.45	5.62	3.95	1.19	0.38	0.28	0.20	1.70	5.14	7.38	9.18	12	14	12	14	16	1.93	0.04	0.01	0.06	0.09	0.04
Prepaid Expenses & Other	0.66	1.05	0.99	0.27	0.31	0.23	0.22	0.08	0.31	0.58	0.72	0.45	0.55	0.41	0.59	0.35	0.64	0.93	1.20	0.98	–	–	–	1.62	–
Total Current Assets	8.25	1.76	3.70	4.72	5.93	4.18	1.42	0.46	0.59	0.78	2.41	5.84	8.42	10	12	14	12	15	17	2.91	–	–	–	1.81	–
Property, Plant & Equipment	0.29	0.31	0.34	0.37	0.40	0.43	0.25	0.18	0.19	0.20	0.21	0.08	0.09	0.09	0.10	0.10	–	–	–	–	–	–	–	–	–
Total Assets	8.54	2.08	4.04	5.09	6.33	4.60	1.67	0.63	0.78	0.98	2.63	5.92	8.50	10	12	15	12	15	17	2.91	–	–	–	1.81	–
Accounts Payable	2.74	1.35	1.86	0.72	0.98	0.63	2.88	2.93	3.83	3.67	2.74	2.87	2.64	0.65	1.03	1.16	0.46	1.13	1.07	0.50	–	–	–	0.93	–
Total Current Liabilities	–	–	–	–	–	–	–	–	3.83	–	–	2.87	2.64	1.64	1.03	1.16	0.47	1.48	1.47	0.90	–	–	–	0.99	–
Total Liabilities	2.74	1.35	1.86	0.72	0.98	0.63	2.88	3.23	4.57	3.67	2.74	2.87	2.64	1.64	1.03	1.16	0.47	1.48	1.47	0.90	–	–	–	0.99	–
Preferred Stock	0.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–	0.00	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	–	–	–	0.01	–
Additional Paid-In Capital	76	68	67	67	67	63	54	51	49	63	62	62	62	59	58	57	52	51	49	34	–	–	–	28	–
Retained Earnings	-70	-67	-64	-62	-61	-59	-55	-54	-53	-51	-48	-44	-41	-35	-32	-29	-25	-23	-19	-17	–	–	–	-12	–
Shareholders' Equity	5.80	0.73	2.20	4.37	5.34	3.97	-1.21	-2.59	-4.26	-2.68	-0.11	3.05	5.86	8.79	11	13	12	13	15	2.01	-1.30	-0.67	0.03	0.82	0.32
Total Equity	5.80	0.73	2.20	4.37	5.34	3.97	-1.21	-2.59	-4.26	-2.68	-0.11	3.05	5.86	8.79	11	13	12	13	15	2.01	-1.30	-0.67	0.03	0.82	0.32
Total Liabilities & Equity	8.54	2.08	4.04	5.09	6.33	4.60	1.67	0.63	0.78	0.98	2.63	5.92	8.50	10	12	15	12	15	17	2.91	–	–	–	1.81	–
Shares Outstanding(shares)	4.83	4.26	3.80	3.80	3.14	0.78	0.10	0.08	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	–	–	0.06	0.05	–	–	–	0.05	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -373.2%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.03
Dividend yield: –